Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Aulbio Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner. The prosecution is located within 1 distinct art unit, indicating a specific technical focus for the company's current application. This centralized approach allows the applicant to concentrate its efforts on a single set of technical requirements and examiner expectations within the Biotechnology & Pharmaceuticals sector.
The busiest examiner is GREENE, IVAN A, who is responsible for 1 pending office action. With 1 distinct examiner and 1 distinct art unit for the 1 pending office action, the portfolio's activity is concentrated. This allows for a focused engagement with the examiner in the Biotechnology & Pharmaceuticals sector. Practitioners should prioritize understanding the specific requirements of the 1 distinct art unit and the preferences of GREENE, IVAN A. Since the entire active portfolio consists of 1 pending office action, the outcome of this case is the primary focus of the company's current prosecution efforts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GREENE, IVAN A | 1 | 18.8% | +6.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18709351 | MICROSPHERES COMPRISING HIGH-DOSE VARENICLINE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREENE, IVAN A | — |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18709351 | MICROSPHERES COMPRISING HIGH-DOSE VARENICLINE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREENE, IVAN A | 1619 | §102§103§112 | Non-Final OA | — | Pending | May 10, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAulbio Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ivan A Greene has the most, with 1 of Aulbio Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
